| Name | Title | Contact Details |
|---|
Besafemeds takes today`s technology and applies it to healthcare to deliver a discreet treatment option for STDs. We store no identifiable data on our users. Once a determination is made that a prescription is needed and subsequently transmitted to the pharmacy of your choice, all identifiable data is purged from the system. Besafemeds is staffed by physicians and nurse practitioners following standard treatment guidelines for the two most common STDs (gonorrhea and chlamydia). In an ideal world, testing should occur before treatment. However, besafemeds is here for those who need or want a discreet and quick STD treatment option.
West Jefferson Medical Center is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. West Jefferson Medical Center is based in Marrero, LA. You can find more information on West Jefferson Medical Center at www.wjmc.org
APS Healthcare, Inc. is a comprehensive managed behavioral healthcare company focusing on the management of mental health services and substance abuse treatment, often referred to together as behavioral healthcare.
Spray-Tek is a Middlesex, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.